ZEB1 and skin squamous cell carcinoma: Based on our results, we propose a combination regimen using a ZEB1 antagonist as an adjuvant along with simultaneous blockade of the CD47-SIRPα immune checkpoint, which may improve the outcomes of the majority of patients with CSCC in part by disinhibiting innate immunity.